Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease
Background: Inflammatory rheumatic diseases regularly require the use of disease-modifying antirheumatic drugs (DMARDs). The use of DMARDs in patients with end-stage chronic kidney disease (CKD stage 5D) is particularly challenging due to the lack of systematic studies available for this...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Kidney & Blood Pressure Research |
| Online Access: | https://karger.com/article/doi/10.1159/000544810 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133682456625152 |
|---|---|
| author | Daniel Patschan Igor Matyukhin Friedrich Stasche Oliver Ritter Susann Patschan |
| author_facet | Daniel Patschan Igor Matyukhin Friedrich Stasche Oliver Ritter Susann Patschan |
| author_sort | Daniel Patschan |
| collection | DOAJ |
| description |
Background: Inflammatory rheumatic diseases regularly require the use of disease-modifying antirheumatic drugs (DMARDs). The use of DMARDs in patients with end-stage chronic kidney disease (CKD stage 5D) is particularly challenging due to the lack of systematic studies available for this patient population. This narrative review aimed to address the aspect of DMARD therapy in CKD 5D. Summary: The current article is a narrative review. References were sourced from the following databases: PubMed, Web of Science, Cochrane Library, and Scopus. The search period spanned from 1975 to 2024. There is a notable lack of systematic data on this topic. The available literature was reviewed to provide insights, despite the limited availability of comprehensive studies. Individuals with terminal kidney disease can presumably be safely treated with leflunomide, mycophenolic acid, sulfasalazine, azathioprine, belimumab, and anti-CD20. For all other substances, there are either significant restrictions, insufficient data, or inadequate experience. Key Messages: Some conventional and biologic DMARDs are available for the management of inflammatory rheumatic diseases in CKD stage 5D. It is essential to consider the limitations on kidney function, as they can significantly affect the pharmacokinetics of medications. Consequently, slightly more frequent checkups are recommended when using the defined preparations. |
| format | Article |
| id | doaj-art-5eea14c62bec437ea6ec972c40228c16 |
| institution | OA Journals |
| issn | 1423-0143 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney & Blood Pressure Research |
| spelling | doaj-art-5eea14c62bec437ea6ec972c40228c162025-08-20T02:31:55ZengKarger PublishersKidney & Blood Pressure Research1423-01432025-01-0150124925810.1159/000544810Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney DiseaseDaniel PatschanIgor MatyukhinFriedrich StascheOliver RitterSusann Patschan Background: Inflammatory rheumatic diseases regularly require the use of disease-modifying antirheumatic drugs (DMARDs). The use of DMARDs in patients with end-stage chronic kidney disease (CKD stage 5D) is particularly challenging due to the lack of systematic studies available for this patient population. This narrative review aimed to address the aspect of DMARD therapy in CKD 5D. Summary: The current article is a narrative review. References were sourced from the following databases: PubMed, Web of Science, Cochrane Library, and Scopus. The search period spanned from 1975 to 2024. There is a notable lack of systematic data on this topic. The available literature was reviewed to provide insights, despite the limited availability of comprehensive studies. Individuals with terminal kidney disease can presumably be safely treated with leflunomide, mycophenolic acid, sulfasalazine, azathioprine, belimumab, and anti-CD20. For all other substances, there are either significant restrictions, insufficient data, or inadequate experience. Key Messages: Some conventional and biologic DMARDs are available for the management of inflammatory rheumatic diseases in CKD stage 5D. It is essential to consider the limitations on kidney function, as they can significantly affect the pharmacokinetics of medications. Consequently, slightly more frequent checkups are recommended when using the defined preparations. https://karger.com/article/doi/10.1159/000544810 |
| spellingShingle | Daniel Patschan Igor Matyukhin Friedrich Stasche Oliver Ritter Susann Patschan Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease Kidney & Blood Pressure Research |
| title | Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease |
| title_full | Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease |
| title_fullStr | Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease |
| title_full_unstemmed | Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease |
| title_short | Disease-Modifying Antirheumatic Drug Therapy of Inflammatory Rheumatic Diseases in End-Stage Kidney Disease |
| title_sort | disease modifying antirheumatic drug therapy of inflammatory rheumatic diseases in end stage kidney disease |
| url | https://karger.com/article/doi/10.1159/000544810 |
| work_keys_str_mv | AT danielpatschan diseasemodifyingantirheumaticdrugtherapyofinflammatoryrheumaticdiseasesinendstagekidneydisease AT igormatyukhin diseasemodifyingantirheumaticdrugtherapyofinflammatoryrheumaticdiseasesinendstagekidneydisease AT friedrichstasche diseasemodifyingantirheumaticdrugtherapyofinflammatoryrheumaticdiseasesinendstagekidneydisease AT oliverritter diseasemodifyingantirheumaticdrugtherapyofinflammatoryrheumaticdiseasesinendstagekidneydisease AT susannpatschan diseasemodifyingantirheumaticdrugtherapyofinflammatoryrheumaticdiseasesinendstagekidneydisease |